Cardiovascular diseases are one of the most significant global health challenges. Abu Dhabi: 'Mubadala Bio' has announced the launch of two new drugs for the treatment of cardiovascular diseases, marking a step towards expanding its pharmaceutical portfolio within one of its key therapeutic areas. The two drugs, ticagrelor and tirofiban, are produced by the company's subsidiaries in the United Arab Emirates. They support the local production of essential treatments that help protect patients from heart attacks and strokes, and enhance access to high-priority healthcare to maintain the health and safety of patients across the UAE.
